Genentech and Biogen Idec have submitted two supplemental Biologics License Applications (sBLAs) to the FDA for Rituxan plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL). The companies will request a priority review, and if granted, anticipate the FDA will make a decision within six months. CLL is the most common type of adult leukemia, accounting for one-third of all leukemias in the U.S. It is a slow-growing disease that occurs whe...